Diroximel Fumarate Delayed-Release Capsules had annual sales of $847.4 million in the United States (IQVIA MAT May 2024)," Zydus said. The group also mentioned that it currently has 398 approvals ...
Zydus Cadila gets USFDA nod to market muscle relaxant in US "The company has received final approval from the US Food and Drug Administration (USFDA) to market tizanidine hydrochloride capsules ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback